Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2023.1345513 Immunology Correction Corrigendum: Soluble PD−L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis Shimizu Takashi 1 2 Inoue Eisuke 3 Ohkuma Ryotaro 1 4 Kobayashi Shinichi 2 Tsunoda Takuya 4 Wada Satoshi 1 2 4 5 6 * 1 Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan 2 Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan 3 Showa University Research Administration Center, Showa University, Tokyo, Japan 4 Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan 5 Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan 6 Pharmacological Research Center, Showa University, Tokyo, Japan

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Satoshi Wada, st-wada@med.showa-u.ac.jp

05 12 2023 2023 14 1345513 27 11 2023 29 11 2023 Copyright © 2023 Shimizu, Inoue, Ohkuma, Kobayashi, Tsunoda and Wada 2023 Shimizu, Inoue, Ohkuma, Kobayashi, Tsunoda and Wada

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis by Shimizu T, Inoue E, Ohkuma R, Kobayashi S, Tsunoda T and Wada S (2023) Front. Immunol. 14:1308381. doi: 10.3389/fimmu.2023.1308381 soluble PD-L1 advanced non-small cell lung cancer PD-1 inhibitors individual patient data meta-analysis biomarker section-in-acceptance Cancer Immunity and Immunotherapy

In the published article, there was an error in the legend for Figure 2 and Figure 3 as published. Figure 2B and Figure 3B ; Hazard ratios of overall death, and Figure 3 legend; B; disease progression. The corrected legend appears below.

Forest plots representing hazard ratios of death (A; overall death, B; disease progression) for sPD-L1 fold changes in each trial.

Forest plots representing hazard ratios of death (A; overall death, B; disease progression) for sPD-L1 changes by subgroup.

Figure 2B and Figure 3B ; Hazard ratios of disease progression, and Figure 3 legend; B; disease progression.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.